SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $288.28M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 0.89M
Average 0.76M
SABS Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
SAB Biotherapeutics, Inc.NASDAQ: SABS
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit turns positive
Q2 FY2026 gross profit was $0, compared with -$822K a year earlier. Trailing-twelve-month gross profit was -$2.28M.
Context
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$570.36K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (3.08M) USD
- Year-over-year change
- +11.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.08M) | +11.2% |
| FY2024 | 2024-12-31 | (3.47M) | -130.4% |
| FY2023 | 2023-12-31 | (1.51M) | -107.3% |
| FY2022 | 2022-12-31 | 20.61M | -65.2% |
| FY2021 | 2021-12-31 | 59.22M | — |
Gross Profit vs competitors
How SABS compares with its peers on the latest reported figures
- SABS's LTM Jun 2026 gross profit of -$2.28M is the lowest of the 5 companies compared; the peer median is $16.63M.
- Its year-over-year change of +77.4% is the 3rd highest of 4, against a peer median of +545.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $53.38M | +14926.4% | +100.2% | 99.3% | |
| LTM Mar 2026 | $33.27M | +545.5% | +57.0% | 89.5% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$1.22M | -359.6% | — | — | |
| LTM Jun 2026 | -$2.28M | +77.4% | — | — | |
| Peer median (excluding SABS) | $16.63M | +545.5% | +78.6% | 94.4% | |
Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 60.88M | 23.9M | 2.24M | 1.32M | 0 |
| Cost of Revenue | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Gross Profit | 59.22M | 20.61M | (1.51M) | (3.47M) | (3.08M) |
| Gross Margin | 97.3% | 86.2% | -67.3% | -262.4% | — |
| Research & Development | 57.18M | 36.44M | 16.52M | 30.16M | 34.35M |
| Selling, General & Admin | 17.09M | 16.38M | 23.8M | 9.28M | 14.6M |
| Operating Expenses | 72.62M | 49.53M | 36.57M | 39.44M | 45.87M |
| Depreciation & Amortization | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| EBITDA | (15.2M) | (15.12M) | (38.13M) | (28.99M) | 16.6M |
| EBITDA Margin | -25.0% | -63.3% | -1703.1% | -2192.5% | — |
| Operating Income | (13.39M) | (28.92M) | (38.08M) | (42.91M) | (48.95M) |
| Operating Margin | -22.0% | -121.0% | -1700.5% | -3244.9% | — |
| Interest Income | 23.12K | 71.07K | 584.97K | 1.29M | 1.43M |
| Interest Expense | 294.46K | 301.58K | 315.28K | 318.4K | 240.66K |
| Other Income / Expenses | (3.75M) | 10.2M | (4.12M) | 8.81M | 62.23M |
| Income Before Tax | (17.15M) | (18.72M) | (42.19M) | (34.11M) | 13.27M |
| Pre-Tax Margin | -28.2% | -78.3% | -1884.5% | -2579.0% | — |
| Income Tax Expense | 0 | 25.63K | 0 | 0 | 0 |
| Net Income | (17.15M) | (18.74M) | (42.19M) | (34.11M) | 13.27M |
| Net Margin | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
| EPS (Basic) | (3.94) | (4.31) | (7.64) | (3.68) | 0.22 |
| EPS (Diluted) | (6.30) | (4.31) | (7.64) | (3.68) | (0.79) |
| Weighted Avg Shares | 4.35M | 4.35M | 5.52M | 9.26M | 19.31M |
| Weighted Avg Shares (Diluted) | 2.73M | 4.35M | 5.52M | 9.26M | 61.34M |
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.